Resolvin E1 improves efferocytosis and rescues severe aplastic anemia in mice.

Autor:	Grazda R; Department of Immunology and Microbiology, Albany Medical College, Albany, New York, USA., Seyfried AN; Department of Immunology and Microbiology, Albany Medical College, Albany, New York, USA.; Current address: Institute for Clinical Pharmacodynamics, Schenectady, NY, USA., Maddipatti KR; Department of Pathology, Lipidomics Core Facility, Wayne State University, Detroit, Michigan, USA., Fredman G; Department of Molecular and Cellular Physiology, Albany Medical College, Albany, New York, USA., MacNamara KC; Department of Immunology and Microbiology, Albany Medical College, Albany, New York, USA.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2023 Aug 02. Date of Electronic Publication: 2023 Aug 02.
DOI:	10.1101/2023.02.15.528688
Abstrakt:	Current treatments for severe aplastic anemia (SAA) rely on hematopoietic stem cell (HSC) transplantation and immunosuppressive therapies, however these treatments are not always effective. While immune-mediated destruction and inflammation are known drivers of SAA, the underlying mechanisms that lead to persistent inflammation are unknown. Using an established mouse model of SAA, we observed a significant increase in apoptotic cells within the bone marrow (BM) and demonstrate impaired efferocytosis in SAA mice, as compared to radiation controls. Single-cell transcriptomic analysis revealed heterogeneity among BM monocytes and unique populations emerged during SAA characterized by increased inflammatory signatures and significantly increased expression of Sirpa and Cd47 . CD47, a "don't eat me" signal, was increased on both live and apoptotic BM cells, concurrent with markedly increased expression of signal regulatory protein alpha (SIRPα) on monocytes. Functionally, SIRPα blockade improved cell clearance and reduced accumulation of CD47-positive apoptotic cells. Lipidomic analysis revealed a reduction in the precursors of specialized pro-resolving lipid mediators (SPMs) and increased prostaglandins in the BM during SAA, indicative of impaired inflammation resolution. Specifically, 18-HEPE, a precursor of E-series resolvins, was significantly reduced in SAA-induced mice relative to radiation controls. Treatment of SAA mice with Resolvin E1 (RvE1) improved efferocytic function, BM cellularity, platelet output, and survival. Our data suggest that impaired efferocytosis and inflammation resolution contributes to SAA progression and demonstrate that SPMs, such as RvE1, offer new and/or complementary treatments for SAA that do not rely on immune suppression. Competing Interests: Conflict-of-interest disclosure: The authors declare no competing financial interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu